Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Codabakalner in Male Participants With Full Mutation Fragile X Syndrome and Adult Participants With Autism Spectrum Disorders

NCT07439510 is registered in ClinicalTrials.gov with Spinogenix as lead sponsor.

NCT NCT07439510
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07439510 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Codabakalner in Male Participants With Full Mutation Fragile X Syndrome and Adult Participants With Autism Spectrum Disorders
Lead sponsor
Spinogenix
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
December 1, 2026
Completion date
June 30, 2030
Enrollment
120 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

autism spectrum disorder (asd), fragile x syndrome (fxs)